Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
66.51(c) 66.67(c) 67.45(c) 66.02(c) 65.57(c) Last
593 700 358 717 503 525 583 674 420 542 Volume
-0.14% +0.24% +1.17% -2.12% -0.68% Change
More quotes
Financials ($)
Sales 2017 445 M
EBIT 2017 -248 M
Net income 2017 -243 M
Finance 2017 198 M
Yield 2017 -
Sales 2018 597 M
EBIT 2018 -140 M
Net income 2018 -168 M
Finance 2018 171 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 20,6x
EV / Sales2018 15,4x
Capitalization 9 358 M
More Financials
Company
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer.Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an... 
More about the company
Surperformance© ratings of Seattle Genetics, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on SEATTLE GENETICS, INC.
05/26 TAKEDA PHARMACEUTICAL : Showcases Broadened Oncology Portfolio Through Data Pres..
05/25 SEATTLE GENETICS : New Findings in Pharmacokinetics Described from Seattle Genet..
05/24 SEATTLE GENETICS, INC. (NASDAQ : SGEN) Files An 8-K Submission of Matters to a V..
05/09 SEATTLE GENETICS : to Present at Bank of America Merrill Lynch 2017 Healthcare C..
05/08 SEATTLE GENETICS : pulls out of $2 billion bid for cancer drug
05/05 SEATTLE GENETICS, INC. (NASDAQ : SGEN) Files An 8-K Entry into a Material Defini..
05/05 SEATTLE GENETICS INC /WA : Entry into a Material Definitive Agreement, Terminati..
05/05 SEATTLE GENETICS : Terminates License Agreement with Immunomedics for Sacituzuma..
05/04 SEATTLE GENETICS : Reports First Quarter 2017 Financial Results
05/01 SEATTLE GENETICS : WA Management's Discussion and Analysis of Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02:53aSeattle Genetics, Inc. $SGEN Shares Bought by Emory University  
05/26Brokerages Expect Seattle Genetics, Inc. $SGEN Will Announce Earnings of -$0... 
05/25KBC Group NV Buys 63,249 Shares of Seattle Genetics, Inc. $SGEN  
05/25Seattle Genetics, Inc. $SGEN Position Increased by Advisors Asset Management .. 
05/25Want automatic email alerts for $SGEN $FANH $BWP $APRI $AGM? Subscribe to Mar.. 
More tweets
Qtime:25
News from SeekingAlpha
05/08 Immunomedics Pushes Forth On Sacituzumab Govitecan
05/07 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 7, 2017
05/05 SEATTLE GENETICS COO : Will remain opportunistic
05/05 Immunomedics +19% on private placement, CEO departure, IMMU-132 news
04/27 Seattle Genetics (SGEN) Q1 2017 Results - Earnings Call Transcript
Advertisement
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Full-screen chart
Technical analysis trends SEATTLE GENETICS,...
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 60,8 $
Spread / Average Target -7,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Eric L. Dobmeier Chief Operating Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.25.11%9 358
INCYTE CORPORATION38.04%27 518
QUINTILES IMS HOLDINGS..11.37%18 872
LONZA GROUP AG23.45%15 703
CELLTRION, INC.--.--%10 293
ALKERMES PLC4.25%8 839
More Results